Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Visonpharma Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, MCANANY, JOHN D, who also serves as the busiest examiner for the portfolio. The prosecution is being handled within a distinct art unit, which provides a specialized context for the evaluation of the company's technology.
Because MCANANY, JOHN D is the only examiner involved, the company can focus its efforts on meeting the specific requirements of this individual. This concentration within the Biotechnology & Pharmaceuticals field allows for a more targeted and effective prosecution strategy. The practitioner can use the busiest examiner's past rulings as a guide for preparing the response to the pending action.
The evaluation of the pending office action within a distinct art unit suggests that the company's intellectual property is being reviewed by a department with deep expertise in the relevant field. This focus can help ensure that the examination is both thorough and consistent. Monitoring the status of the pending action is important for understanding the current examination landscape for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCANANY, JOHN D | 1 | 65.1% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717807 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | MCANANY, JOHN D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717807 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | MCANANY, JOHN D | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717807 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | MCANANY, JOHN D | 1625 | §102§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Visonpharma Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John D Mcanany has the most, with 1 of Shanghai Visonpharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
